CST, 29442S, Concanamycin A

Chemical Modulators for studying in the research area. Product Usage Information Concanamycin A is supplied as a lyophilized powder. For a 20 μM stock, reconstitute 20 μg of powder in 1.15 mL of DMSO. Working concentrations and length of treatment can vary depending on the desired effect. Storage Store lyophilized at -20ºC, desiccated. In lyophilized form, the chemical is stable for 24 months. Once in solution, store at -20ºC and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles . Background Concanamycin A is a macrolide antibiotic derived from that is effective against several fungi and yeasts (1). Concanamycin A is an exceptionally potent and specific inhibitor of the ATP-driven proton pumps known as vacuolar type H+-ATPases (V-ATPases). V-ATPases acidify intracellular compartments and translocate protons across the plasma membrane. Intracellular V-ATPases play an important role in endocytosis and intracellular membrane trafficking, while plasma membrane V-ATPases are important in processes such as urinary acidification and bone resorption (2). Treatment of murine cells with Concanamycin A results in apoptosis, evidenced by an increase in fragmented DNA and the number of apoptotic cells with hypodiploid DNA (3). Concanamycin A induced production of nitric oxide and decreased cell growth and survival in mouse leukemic monocyte cells (4). Concanamycin A reversed the downregulation of cell surface MHC-I by the HIV-encoded accessory protein Nef, suggesting a possible therapeutic role of Concanamycin A in enhancing the immune-mediated clearance of HIV-infected cells (5). Alternate Names Folimycin